Hepatitis C Virus
Pharmasset Initiates Multiple Ascending Dose Study of R7128 in Patients Chronically Infected with HCV Genotype 1
Published in Hepatitis Weekly, March 19th, 2007
Pharmasset initiated the multiple ascending dose portion of an on-going Phase 1 clinical trial evaluating R7128 in up to 40 patients chronically infected with hepatitis C virus (HCV) genotype 1. The primary objective of this part of the study, being conducted in collaboration with Roche, is to assess the safety, tolerability and pharmacokinetics of multiple doses of R7128 after once-daily or twice-daily dosing for 14 days. The secondary objective is to assess antiviral efficacy of R7128 by measuring the decrease in HCV viral load. As a result of the initiation of the multiple ascending dose portion of this study, Pharmasset triggered a $5.0 million milestone payment from Roche.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-03-19)
More Articles from Hepatitis Weekly
- Hepatocellular Cancer
Outcomes for patients with hepatitis B who need liver transplants - Hepatitis B Virus
Idenix Announces Thirteen Data Presentations at the 2007 European Association For the Study of the Liver - Hepatitis B Virus
Sebivo approved in China for treatment of chronic hepatitis B, the nation's second leading cause of death - Hepatitis C Virus
Nautilus Biotech and HanAll Pharmaceutical Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea - Hepatitis E Virus
Study published in New England Journal of Medicine: Vaccine 95.5% effective against neglected hepatitis E - HIV/AIDS
Cerus Corporation Awarded Grants for Its Listeria-Based Vaccine Platforms - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
